Skip to content
Matrix Global Advisors
Matrix Global Advisors
  • Home
  • About
  • News
  • Our Work
  • Contact
  • Home
  • About
  • News
  • Our Work
  • Contact
Sep152020
News

Brand-name Drugmaker Tactic ‘Product Hopping’ Costs US Healthcare System $4.7 Billion Annually, Study Says

Maia Anderson | Becker’s Hospital Review

“An anti-competitive tactic used by brand-name drugmakers called product hopping costs the U.S. healthcare system at least $4.7 billion annually, according to a study from Matrix Global Advisors.

The study — released Sept. 1 from the Washington, D.C.-based economic policy consulting firm and commissioned by the Coalition for Affordable Prescription Drugs — studied the effects of product hopping on the U.S. healthcare system.”

Read Here

September 15, 2020Category: News
Tags: drug competitiongeneric drugproduct hopping

Post navigation

PreviousPrevious post:A Deal for Coronavirus Fiscal ReliefNextNext post:New Report Shows Brand Drug Product Hopping Costs Billions for Patients and Healthcare System Each Year
  • Analysis(29)
  • Books(2)
  • Events(13)
  • Interviews(35)
  • News(45)
  • Op-Eds(60)
  • Press Releases(2)
  • Testimony(18)
  • The American Rescue Plan’s Likely Cost is Way More Than $1.9 Trillion
    March 4, 2021
  • Pick Your Child Tax Credit
    March 2, 2021
  • The Tax Benefits of Parenthood: A History and Analysis of Current Proposals
    February 23, 2021
  • MGA Analysis of Potential Savings from Complex Generics Cited in Multiple Publications
    February 12, 2021

Website Design and Developed by DreamBig Creative